Gene expression markers for response to EGFR inhibitor drugs

Details for Australian Patent Application No. 2004248140 (hide)

Owner Genomic Health, Inc.

Inventors Natale, Ronald; Agus, David; Baker, Joffre B.; Shak, Steven

Agent Griffith Hack

Pub. Number AU-A-2004248140

PCT Pub. Number WO2004/111273

Priority 60/474,908 30.05.03 US

Filing date 28 May 2004

Wipo publication date 23 December 2004

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

22 December 2005 PCT application entered the National Phase

  PCT publication WO2004/111273 Priority application(s): WO2004/111273

25 May 2006 Change of Name(s) of Applicant(s), Section 104

  Genomic Health, Inc. The name of the applicant has been changed to Cedars-Sinai Medical Center; Genomic Health, Inc.

14 January 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004248145-Catalyst additives for the removal of NH3 and HCN from a gas flue of a regeneration zone in a catalytic cracking process

2004248138-Targeted delivery to legumain-expressing cells